Development of macitentan for the treatment of pulmonary arterial hypertension
Author:
Affiliation:
1. Actelion Pharmaceuticals, US, Inc South San Francisco California
2. Pulmonary and Critical Care, Massachusetts General Hospital Boston Massachusetts
3. Actelion Pharmaceuticals Ltd Allschwil Switzerland
Funder
Actelion Pharmaceuticals
Publisher
Wiley
Subject
History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.12856
Reference97 articles.
1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Medical Therapy for Pulmonary Arterial Hypertension
3. ADEMPAS® (riociguat) tablets for oral use. Full prescribing information.2014.Whippany NJ:Bayer HeathCare Pharmaceuticals Inc.
4. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
5. Updated Treatment Algorithm of Pulmonary Arterial Hypertension
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China;Current Medical Research and Opinion;2024-08
2. Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension;Frontiers in Pharmacology;2022-06-20
3. Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma;Cancers;2022-03-30
4. Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update;Drug, Healthcare and Patient Safety;2019-09
Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
5. Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema;Expert Opinion on Pharmacotherapy;2018-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3